The ICERs reported in the included studies which are deemed cost-effective were as follows: In one study (19), for patients with PD-L1 expression levels ≥50% and ≥1% or a high Tumor Mutational Burden (TMB), the ICERs were $107,404 and $133,732 per QALY gained, respectively (19). Here, CD274 is linked to neoplasm.